13F Holdings
中文EN

PRTA PROTHENA CORP PUBLIC LTD CO

Pharmaceutical Preparations · Nasdaq · SEC CIK 1559053 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY347.4%
TTM net income YoY91.5%
TTM EPS YoY91.3%
Revenue 3-yr CAGR-27.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-64.6%
Net margin-45.4%
FCF margin—
EBITDA margin-63.1%

Returns

ROE-8.5%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets5.2%
Debt / equity0.00x
Current ratio23.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.31x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.68M$135.16M$91.37M$53.91M$200.58M
R&D expense$134.85M$222.52M$220.57M$135.56M$82.28M
SG&A expense$59.39M$67.20M$61.84M$49.90M$46.32M
Operating income-$214.64M-$154.56M-$191.04M-$131.56M$71.97M
Pretax income-$200.83M-$128.93M-$160.48M-$125.61M$71.92M
Income tax$43.26M-$6.62M-$13.45M-$8.66M$4.95M
Net income-$244.09M-$122.31M-$147.03M-$116.95M$66.97M
EBITDA-$213.75M-$153.67M-$190.11M-$130.81M$73.09M
EPS (basic)-4.53-2.27-2.76-2.471.51
EPS (diluted)-4.53-2.27-2.76-2.471.38
Weighted avg. shares (diluted)53.83M53.77M53.22M47.37M48.46M
Banking
Net interest income$14.14M$25.82M$31.01M$6.35M$42,000
Balance sheet
Cash & equivalents$307.53M$472.25M$618.83M$712.62M$580.45M
Receivables—$0$5.16M$0$0
Current assets$315.19M$485.41M$639.28M$719.10M$584.81M
PP&E, net$2.14M$3.08M$3.84M$1.73M$2.01M
Total assets$326.80M$547.11M$696.38M$758.03M$609.37M
Current liabilities$40.84M$48.50M$56.89M$50.15M$33.45M
Total liabilities$46.33M$60.18M$135.02M$135.99M$143.32M
Shareholders' equity$280.47M$486.93M$561.37M$622.04M$466.04M
Shares outstanding53.83M53.83M53.68M52.10M46.66M
Cash flow statement
Operating cash flow-$163.58M-$150.05M-$133.91M-$108.82M$92.61M
Investing cash flow-$138,000-$298,000-$2.77M-$464,000-$575,000
Financing cash flow-$139,000$1.55M$45.10M$241.46M$190.33M
Depreciation & amortization$895,000$893,000$928,000$744,000$1.11M
Stock-based compensation$37.64M$45.96M$40.91M$31.32M$24.66M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.